Martinez Maria, Tsakiris Dimitrios A
Diagnostic Hematology, University Hospital Basel, CH-4031 Basel, Switzerland.
Dent J (Basel). 2015 Oct 6;3(4):93-101. doi: 10.3390/dj3040093.
Systemic anticoagulation with intravenous or oral anticoagulants and antiplatelet agents is an efficient treatment against thromboembolic or cardiovascular disease. Invasive dental procedures or oral surgery might be associated with bleeding complications if carried out under anticoagulants. Patients on vitamin K antagonists, new direct anticoagulants or antiplatelet agents having dental interventions with low-risk for bleeding do not need interruption of anticoagulation. In case of bleeding complications local hemostatic measures, such as local surgical sutures, fibrin glue, local antifibrinolytic treatment with tranexamic acid, or e-aminocaproic acid suffice to stop bleeding. In patients with high risk of bleeding an individual assessment of the benefit/risk ratio of interrupting anticoagulation should be carried out. Bridging the long-term anticoagulation with short-term anticoagulants should be planned according to national or international guidelines. The introduction of the newer direct oral anticoagulants having more flexible pharmacokinetic properties has facilitated bridging, allowing short-term interruption without increasing the risk of relapsing thrombotic or cardiovascular events.
使用静脉或口服抗凝剂及抗血小板药物进行全身抗凝是治疗血栓栓塞性疾病或心血管疾病的有效方法。在抗凝治疗期间进行侵入性牙科手术或口腔外科手术可能会引发出血并发症。服用维生素K拮抗剂、新型直接抗凝剂或抗血小板药物且进行出血风险较低的牙科干预的患者无需中断抗凝治疗。若出现出血并发症,局部止血措施,如局部手术缝合、纤维蛋白胶、用氨甲环酸或ε-氨基己酸进行局部抗纤溶治疗,足以止血。对于出血风险高的患者,应进行个体评估以确定中断抗凝治疗的获益/风险比。应根据国家或国际指南规划使用短期抗凝剂进行长期抗凝的桥接治疗。新型直接口服抗凝剂具有更灵活的药代动力学特性,这有助于进行桥接治疗,允许短期中断治疗而不增加复发性血栓形成或心血管事件的风险。